Expanding the Curative Potential of CAR T-Cell Therapy

Multiple Myeloma (MM)

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

Blood Cancer J

Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD Jr, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri CJ

doi: 10.1038/s41408-026-01469-z

Lymphoma

CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis

Am J Hematol

Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, Delgado J, Grover N, Haverkos B, de Lima M, Malone A, Mussetti A, Nieto Y, Pawarode A, Pearson L, Solh M, Sureda A, Tun AM, Wudhikarn K, Yamshon S, Shadman M, Turtle CJ, Hamadani M, Herrera AF

doi: 10.1002/ajh.70033

Further Publications

A Bright Future for Immunotherapy: CAR T-Cell Therapy Promises Revolutionary Changes

healthbook TIMES Onco Hema

Rybachuk VA, Evstratova ES, Klabukov ID, Ivanov SA, Shegai PV, Kaprin AD, Baranovsky DS

doi: 10.36000/HBT.OH.2024.22.164

ASH 2025

Multiple Myeloma (MM)

LBA-1: Early MRD negativity following the novel in vivo CAR T-cell therapy KLN-1010 in patients with RRMM

ASH 2025

Lymphoma

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

Multiple Myeloma (MM)

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

Blood Cancer J

Hashmi H, Sebastian T, Rajeeve S, Farzana T, Firestone RS, Jurgens EM, Miller KC, Maura F, Lesokhin AM, Tan CR, Shah GL, Korde N, Landau HJ, Merz M, Scordo M, Hassoun H, Maclachlan KH, Shah UA, Hultcrantz ML, Derkach A, Nemirovsky D, Giralt S, Mailankody S, Usmani SZ

doi: 10.1038/s41408-026-01494-y

Lung, Respiratory and Thoracic Cancer

CAR-T cell therapy for the treatment of lung cancer: Current challenges and emerging therapeutic strategies

Lung Cancer

Shi D, Yan X, Liu J, Chen H, Wang X, Li R, Tian X, Lin X, Wang Y

doi: 10.1016/j.lungcan.2025.108849

Further Publications

Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials

Am J Hematol

Filippatos C, Kanteli I, Pasipoularidou DG, Gavriatopoulou M, Tentolouris A, Malandrakis P, Sergentanis TN, Terpos E, Ntanasis-Stathopoulos I

doi: 10.1002/ajh.70201

Multiple Myeloma (MM)

Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy

Blood

Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees MJ, Costello P, Vazquez Martinez MA, Pasvolsky O, Wagner CB, Davis JA, Castaneda Puglianini OA, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo RD, Freeman CL, Mikkilineni L, Raza S, Anderson LD Jr, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Gagelmann N, Kumar AD, Hansen DK, Cowan AJ, Costa LJ, Merz M, Sidana S

doi: 10.1182/blood.2025029773

Related content

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis

A Bright Future for Immunotherapy: CAR T-Cell Therapy Promises Revolutionary Changes

LBA-1: Early MRD negativity following the novel in vivo CAR T-cell therapy KLN-1010 in patients with RRMM

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

CAR-T cell therapy for the treatment of lung cancer: Current challenges and emerging therapeutic strategies

Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials

Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy